Rebecca Emeny, PhD, MPH

Research Scientist, The Dartmouth Institute for Health Policy and Clinical Practice and Research Design and Epidemiology Core, Dartmouth Synergy





  • MPH, Ludgwig-Maxilimilan’s University, Epidemiology & Biostatistics
  • PhD, University of New Mexico, Biomedical Sciences
  • BS, Cornell University, Technology & Society

Short Bio

Rebecca Emeny’s translational research interests focus on basic, clinical, and epidemiologic research. Part of her work involves translating population-based evidence into clinically meaningful practice. She has conducted epidemiologic studies that revealed epigenetic and metabolic correlates of stressors commonly occurring in generally healthy adults. These neuroendocrine-immune alterations promote chronic inflammation and diseases such as Type 2 diabetes and coronary heart disease but are modifiable through stress-buffering activities (exercise and sleep) as well as psychological wellbeing and resilience. Her work with the Munich Cancer Registry on data-driven models generated hypotheses of tumor initiation and progression that may inform clinical guidelines. Her current research at The Dartmouth Institute uses Medicare claims data to identify risky drug prescribing patterns in adult populations, providing real world evidence that may guide clinicians in prescribing decisions.